PrintNew Drug Approvals in March 2011
| Country of Approval | Company | Compound | Indication |
| United States | GSK Human Genome Sciences |
Benlysta (belimumab) | Autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy |
| Bristol-Myers Squibb | Yervoy (ipilimumab) | Unresectable advanced melanoma | |
| Canada | Novartis | Gilenya (fingolimod) | Multiple sclerosis |
| Europe | InterMune | Esbriet (pirfenidone) | Idiopathic pulmonary fibrosis |
| Novartis | Gilenya (fingolimod) | Multiple sclerosis | |
| Taiho Pharma (Otsuka Pharmaceutical) | Teysuno (tegafur / gimeracil / oteracil) | Advanced gastric (stomach) cancer - Used in combination with cisplatin | |
| Janssen-Cilag (Johnson & Johnson) | Xeplion (paliperidone) | Schizophrenia | |
| Japan | Roche | Herceptin | New indication: Stomach cancer |
April 25, 2011
http://www.burrillreport.com/article-drug_approvals_in_2011.html
.gif)
